Melatonin Use in Children Surges Amid Safety and Regulatory Concerns

Rise in Melatonin Use Among Children

Melatonin, a hormone regulating sleep-wake cycles, has seen increased use among children globally, driven by its availability as an over-the-counter supplement and perception as a safe alternative to prescription medications. A 2026 JAMA Network Open review noted a significant rise in melatonin use among children aged 6 and younger over two decades. In regions requiring prescriptions, such as parts of Europe and Canada, prescription rates have climbed by up to 500% since 2010. However, melatonin remains unregulated in many countries, including the U.S., where it is classified as a dietary supplement. The review also highlighted extended use, with refills occurring two to three years after initial prescriptions, prompting concerns about long-term safety.

Accessibility and Risks of Accidental Ingestion

Parents are drawn to melatonin for its perceived ease of use and minimal side effects, with products available in child-friendly forms like gummy candies or liquid drops. This accessibility has led to a surge in accidental ingestions, as reported by the U.S. Centers for Disease Control and Prevention (CDC). Between 2019 and 2022, over 11,000 cases of unsupervised melatonin ingestion were documented, many involving gummy formulations resembling candy. These incidents underscore risks tied to widespread use in young children, despite its popularity as a sleep aid. The serper_web_search_tool source identified melatonin as the leading cause of unsupervised medication ingestion in children under 5, emphasizing the need for regulatory action.

“The review also highlighted extended use, with refills occurring two to three years after initial prescriptions, prompting concerns about long-term safety.”

Limited Evidence for Typically Developing Children

While melatonin shows potential for children with neurodevelopmental conditions like autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), its effectiveness and safety for typically developing children remain unclear. A 2026 World Journal of Pediatrics review found that most clinical trials focus on short-term outcomes or specific populations, leaving gaps in data for typically developing children. For instance, studies indicate melatonin may help children with ASD fall asleep faster and improve sleep duration, but long-term effects or efficacy for children without developmental conditions lack evidence.

Regulatory Challenges and Dosage Variability

The lack of long-term data raises concerns about potential impacts on puberty, immune function, metabolism, or neurological development. Most randomized trials have focused on older children or teenagers, leaving younger users—where melatonin use is rising—understudied. This research gap highlights the need for comprehensive studies to evaluate safety, effectiveness, and appropriate use in pediatric care.

Regulatory challenges further complicate melatonin use. A 2026 study by the American Academy of Sleep Medicine (AASM) and the American Academy of Pediatrics (AAP) found significant variability in melatonin content across commercial supplements. Some products contained up to four times the labeled dose, while others had less than half. This inconsistency raises concerns about over- or under-dosing, which could lead to adverse effects such as excessive sleepiness, gastrointestinal issues, dizziness, or respiratory failure.

FDA Classification and Recommendations

The U.S. Food and Drug Administration (FDA) classifies melatonin as a dietary supplement, exempting it from strict medication regulations. This framework allows manufacturers to make unverified health claims without standardized oversight. The AASM and AAP advise consulting a pediatrician before administering melatonin, as sleep issues may be managed through behavioral interventions. The Council for Responsible Nutrition has issued voluntary guidelines for child-deterrent packaging and improved labeling, though these are not universally adopted. The FDA has not established specific guidelines for melatonin supplements in children, leaving safety and use responsibilities to manufacturers and healthcare providers.

Prioritizing Non-Pharmacological Strategies

“Between 2019 and 2022, over 11,000 cases of unsupervised melatonin ingestion were documented, many involving gummy formulations resembling candy.”

Health authorities and pediatricians urge caution in melatonin use for children, emphasizing medical supervision and evidence-based approaches. The AASM and AAP state melatonin should not be used routinely for childhood sleep problems. Instead, they recommend prioritizing sleep hygiene practices, such as consistent bedtime routines, limiting screen exposure, and ensuring age-appropriate sleep expectations. These non-pharmacological strategies are considered first-line treatments for insomnia in children, addressing root causes without exposing children to risks.

Safe Use Guidelines and Expert Recommendations

When melatonin is used, experts advise starting with the lowest effective dose under medical supervision. The Sleep Foundation suggests dosages ranging from 1-2 mg for preschoolers to 1-5 mg for adolescents, with adjustments based on individual needs. However, these recommendations are not FDA-specific and should be combined with professional medical advice. The American Academy of Pediatrics warns against using melatonin in children under 5 without specialist guidance due to overdose risks. The AASM and AAP also recommend selecting products with the USP Verified Mark, indicating compliance with Good Manufacturing Practice (GMP) standards and label accuracy. However, the USP Verified Mark is voluntary, and not all products carry it.

Calls for Regulation and Research

Growing concerns about melatonin use have prompted calls for stricter regulation, clearer labeling, and more long-term research to ensure safety and efficacy. Experts stress that behavioral sleep strategies remain the most effective and safest approach for childhood insomnia. These strategies include consistent sleep schedules, daytime physical activity, and creating a sleep-conducive environment. By focusing on these evidence-based methods, parents and caregivers can reduce reliance on supplements while fostering healthy sleep habits. To address regulatory gaps, the AASM and AAP advocate for mandatory child-deterrent packaging, standardized labeling, and comprehensive clinical trials to evaluate long-term effects in typically developing children. As melatonin use continues to rise, these measures could ensure children receive safe, effective, and evidence-based support for healthy sleep without unnecessary risks.